Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    XmAb5574-01
Show Display Options
Rank Status Study
1 Completed Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Biological: XmAb5574

Indicates status has not been verified in more than two years